Poly Medicure Limited has submitted to the Exchange, the Audited financial results(Standalone & Consolidated) for the period ended March 31, 2026.
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Poly Medicure reported FY2026 consolidated revenue of ₹5,345 crore, up 21% from ₹4,408 crore in FY2025, driven by new acquisitions including Pendracare Group (Netherlands) and Medlstream SA/Citieffe Group (Switzerland). Standalone revenue grew 21% to ₹4,430 crore. Net profit after tax on consolidated basis increased marginally to ₹3,386 crore from ₹3,313 crore, while standalone PAT declined to ₹3,360 crore from ₹3,385 crore. EPS (consolidated) dropped to ₹31.79 from ₹34.13, indicating margin compression despite revenue growth. The company recorded an exceptional item of ₹68.04 crore due to impact of new Labour Codes. Board recommended dividend of ₹3.5 per share (70%). QIP funds of ₹1,000 crore raised previously were deployed for acquisitions and capital expenditure.
Revenue growth exceeds 20% but bottom-line declined or stagnated, suggesting margin pressure from acquisitions and Labour Code impact. The aggressive acquisition strategy is expanding scale but may weigh on near-term profitability and EPS.